Renowned USC/Norris Cancer Researcher, Dr. Heinz-Josef Lenz, Joins Panther Biotechnology Board Of Directors

CHICAGO, IL--(Marketwired - September 11, 2014) -

Panther Biotechnology, Inc. (OTC Pink: PBYA) (PINKSHEETS: PBYA) announced today that Heinz-Josef Lenz, M.D., F.A.C.P., associate director of clinical research at USC/Norris Comprehensive Cancer Center and co-chair of the Southwest Oncology Group’s Gastrointestinal Committee, has been appointed to Panther Biotechnology’s Board of Directors.

As an active cancer researcher at USC/Norris, Dr. Lenz focuses on the regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, and determination of carcinogenesis, methods of early detection, and better surveillance of these cancers. As Associate Director for Clinical Research, Dr. Lenz oversees the activities of the Gastrointestinal Cancers, Genitourinary Cancers, Women’s Cancers, and Leukemia and Lymphoma Programs.

“Dr. Lenz is a dynamic, award-winning leader in the clinical cancer research field,” said Irwin Zalcberg, chairman of Panther Biotechnology, Inc. “His expertise is imperative in the development of important cancer treatments and to shepherd these treatments through early and later stage clinical studies. We’re very excited about his contributions to our company.”

Dr. Lenz is a member of the National Cancer Institute (NCI) Task Force for Gastroesophageal Cancer, the NCI Steering Committee and the NCI Translational Science Committee. In addition to having an NCI-funded laboratory, he was a recipient of the ASCO Young Investigator Award, the ASCO Career Development Award, and the STOP Cancer Career Development Award.

Dr. Lenz is also a member of the American Association for Cancer Research, the American Gastroenterology Association, and the National Society of Genetic Counselors. Dr. Lenz also serves on the National Advisory Board of a number of professional organizations. Dr. Lenz authored many peer-reviewed publications and invited papers, reviews and editorials.

Panther Biotechnology, Inc. is a newly-formed entity focused on the acquisition and development of therapeutics for the treatment of leukemia, lymphoma, myeloma and other cancers. The company will focus on identifying promising anti-cancer therapeutic candidates that are optimized derivatives of widely studied products or re-purposed existing marketed compounds.

Panther Biotechnology, Inc.

Panther Biotechnology, Inc. is a newly-formed entity focused on the acquisition and development of therapeutics for the treatment of leukemia, lymphoma, myeloma and other cancers. The company will focus on identifying promising anti-cancer therapeutic candidates that are optimized derivatives of widely studied products or re-purposed existing marketed compounds. The first product candidate, Numonafide, will be evaluated for the treatment of patients with Acute Myeloid Leukemia (AML). The AML market is anticipated to grow to $1.67 billion dollars by 2020 in G8 countries and it is Panthers belief that there are insufficient treatment options available to treat patients.